RxDoctor Payments Data

Carla Soler, MD

Family Medicine · Murrieta, CANPI 1407836687

Payments from drug & device makers

$2,276in general payments, 2019–2025

Across 117 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$371
  • Novo Nordisk$322
  • Boehringer Ingelheim$191
  • AbbVie$151
  • Amgen$130
  • AstraZeneca$121
  • plus $989 from 27 others

What the payments were for

  • Food & beverage$2,26499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,276 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$33,002
Medicare patients
99
Services billed
2,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide52$63,762
TrulicityDulaglutide59$60,513
JardianceEmpagliflozin40$45,574
EliquisApixaban39$32,862
OzempicSemaglutide22$19,951
MyrbetriqMirabegron21$14,930
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,617
Breo ElliptaFluticasone/Vilanterol14$5,467
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,587
Omeprazole73$1,431
Atorvastatin Calcium149$1,413
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$1,337
Gabapentin44$1,194
Levothyroxine Sodium125$1,181
Rosuvastatin Calcium91$1,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$371$124,275111 claims
Boehringer IngelheimJardiance$191$45,57440 claims
PfizerEliquis$80$32,86239 claims
Novo NordiskOzempic$322$19,95122 claims
GSKTrelegy Ellipta, Breo Ellipta$89$15,08529 claims
Astellas Pharma US IncMyrbetriq$62$14,93021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →